骨髓瘤

ide-cel 早期复发后 BCMA 靶向双特异性抗体治疗结局不佳：一项法国真实世界研究

Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

双特异性抗体在多发性骨髓瘤中的演进

The evolution of bispecific antibodies in multiple myeloma.

无限可能以及如何利用它们？最佳治疗顺序是什么？

Endless possibilities and how to exploit them? What is the optimal treatment sequence?

多发性骨髓瘤 CAR 治疗的靶点

Targets for CAR Therapy in Multiple Myeloma.

多发性骨髓瘤治疗前线的革命：寻找治愈方法的经验与挑战

Revolutions at the frontline of multiple myeloma treatment: lessons and challenges to finding a cure.

病例报告：双靶向 BCMA 和 CS1 CAR-T 细胞免疫治疗复发/难治性髓外多发性骨髓瘤

Case report: Dual-targeted BCMA and CS1 CAR-T-cell immunotherapy in recurrent and refractory extramedullary multiple myeloma.

在接受多轮化疗和放疗的复发难治性多发性骨髓瘤患者中，针对 BCMA 和 CS1 的双靶点 CAR-T 细胞疗法未能有效控制髓外复发。多发性骨髓瘤中 MYBL2 表达升高与较差的预后相关。

多发性骨髓瘤当前的新型靶向治疗策略

Current Novel Targeted Therapeutic Strategies in Multiple Myeloma.

超越骨髓：髓外多发性骨髓瘤肿瘤综合下一代测序的见解

Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors.

多发性骨髓瘤中 CAR-T 或 BiTE 治疗的患者选择：每位患者应选择哪种治疗？

Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?

多发性骨髓瘤靶向免疫治疗新前沿的潜力抗原

Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma.